Chugai Pharmaceutical

AdipoSeeds develops a platelet-making system that generates platelets from mesenchymal stem cells without complex and costly gene transfer. The company aims to address global platelet shortages by enabling a future in which platelet-related treatments are cheaply and safely provided, supported by a new blood supply system. Its technology also leverages adipose-derived materials to produce fat-derived platelets for blood products and wound care medicine, positioning AdipoSeeds to serve biotechnology clients seeking innovative platelet-based solutions.

Preferred Networks, Inc. is a software development company based in Tokyo, Japan, founded in 2014. It specializes in real-time machine learning technologies and develops applications for the Internet of Things, focusing on deep learning, robotics, and data analytics. The company serves various sectors, including transportation systems, manufacturing, bio-healthcare, retail, automobile, healthcare, advertising, life sciences, public safety, network security, and public transportation. Preferred Networks integrates data from the physical and digital worlds to create advanced solutions for autonomous driving, machine tools, robotics, and medical diagnosis. Additionally, the company has a subsidiary in Burlingame, California, which supports its international operations.

iPS PORTAL, Inc. is a Kyoto-based company established in 2014 that specializes in the development of instruments for analyzing and measuring cells, with a particular focus on induced pluripotent stem (iPS) cell technology. The company offers contract testing services for iPS cells, supporting researchers and healthcare companies in the practical application of this technology. Its services encompass research and development outsourcing, concept planning, and training programs in cell culture, all aimed at facilitating the advancement of drug discovery and regenerative medicine. By promoting the widespread use of iPS cell technology, iPS PORTAL plays a vital role in accelerating research and commercialization efforts within the healthcare sector.

TWO CELLS is engaged in the research and development of regeneration technology. The company was founded in April 2003 and is based in Tokyo, Japan.

Gen-Probe Incorporated specializes in the development, manufacturing, and marketing of nucleic acid probe-based products for the clinical diagnosis of human diseases and the screening of donated blood. The company's clinical diagnostic products, sold directly in the United States and through distributors internationally, include assays for detecting viral and non-viral microorganisms, as well as cancer markers. Key offerings include the AccuProbe and PACE product lines, which provide high-sensitivity detection of various pathogens. Additionally, Gen-Probe collaborates with partners such as Novartis, Siemens, and bioMérieux to distribute blood screening products globally and to develop new assays for industrial testing applications. The company is also engaged in the creation of NAT assays and instruments aimed at detecting harmful pathogens in environmental and manufacturing contexts.